{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:42:23Z","timestamp":1790167343084,"version":"4.1.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["F30CA268778"],"award-info":[{"award-number":["F30CA268778"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA208623"],"award-info":[{"award-number":["R01CA208623"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["1R01NS139461"],"award-info":[{"award-number":["1R01NS139461"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Oxaliplatin is a platinum-based alkylating chemotherapeutic agent used for cancer treatment. At high cumulative dosage, the negative effect of oxaliplatin on the heart becomes evident and is linked to a growing number of clinical reports. The aim of this study was to determine how chronic oxaliplatin treatment causes the changes in energy-related metabolic activity in the heart that leads to cardiotoxicity and heart damage in mice. C57BL\/6 male mice were treated with a human equivalent dosage of intraperitoneal oxaliplatin (0 and 10\u00a0mg\/kg) once a week for eight weeks. During the treatment, mice were followed with ECG, histology and RNA sequencing of the heart. We identified that oxaliplatin induces strong changes in the heart and affects the heart\u2019s energy-related metabolic profile. Histological post-mortem evaluation identified focal myocardial necrosis infiltrated with a small number of associated neutrophils. Accumulated doses of oxaliplatin led to significant changes in gene expression related to energy related metabolic pathways including fatty acid (FA) oxidation and glycolysis leading to the glycolysis switch. Our study can be used for the development of diagnostic methods to detect oxaliplatin-induced cardiotoxicity at an early stage and identifying therapeutic methods to minimize heart failure.<\/jats:p>","DOI":"10.1186\/s40959-026-00453-7","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:04:50Z","timestamp":1770969890000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Oxaliplatin-induced cardiotoxicity in mice is connected to the changes in energy metabolism in the heart tissue"],"prefix":"10.1186","volume":"12","author":[{"given":"Junwei","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leland C.","family":"Sudlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiana","family":"Shahverdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan S.","family":"Michie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas H.","family":"Schindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamim","family":"Mollah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail Y.","family":"Berezin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"issue":"2","key":"453_CR1","first-page":"106","volume":"8","author":"EI Syrigou","year":"2009","unstructured":"Syrigou EI, Karapanagiotou EM, Alamara CV, Boura PG, Saif MW, Syrigos KN. Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol. Clin Colorectal Cancer. 2009;8(2):106\u20139.","journal-title":"Clin Colorectal Cancer"},{"issue":"5 Suppl 15","key":"453_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1053\/sonc.2002.35524","volume":"29","author":"J Cassidy","year":"2002","unstructured":"Cassidy J, Misset J-L. Oxaliplatin-related side effects: characteristics and management. Semin Oncol. 2002;29(5 Suppl 15):11\u201320.","journal-title":"Semin Oncol"},{"issue":"Suppl 2","key":"453_CR3","first-page":"S26","volume":"24","author":"NP Staff","year":"2019","unstructured":"Staff NP, Cavaletti G, Islam B, Lustberg M, Psimaras D, Tamburin S. Platinum-induced peripheral neurotoxicity: from pathogenesis to treatment. J Peripher Nerv Syst. 2019;24(Suppl 2):S26\u201339.","journal-title":"J Peripher Nerv Syst"},{"issue":"4","key":"453_CR4","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.21873\/anticanres.14207","volume":"40","author":"D Watanabe","year":"2020","unstructured":"Watanabe D, Fujii H, Matsuhashi N, Iihara H, Yamada Y, Ishihara T, Takahashi T, Yoshida K, Suzuki A. Dose adjustment of oxaliplatin based on renal function in patients with metastatic colorectal cancer. Anticancer Res. 2020;40(4):2379\u201386.","journal-title":"Anticancer Res"},{"issue":"1","key":"453_CR5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s12035-025-05463-7","volume":"63","author":"J Du","year":"2026","unstructured":"Du J, Sudlow LC, Shahverdi K, Zhou H, Yuede CM, Crock LW, Hunter DA, Golden J, Mollah SA, Wood MD. Chronic oxaliplatin treatment induces CIPN in mice via activation of the TXNIP pathway. Mol Neurobiol. 2026;63(1):92.","journal-title":"Mol Neurobiol"},{"key":"453_CR6","doi-asserted-by":"publisher","first-page":"111082","DOI":"10.1016\/j.jinorgbio.2020.111082","volume":"208","author":"SD Dannen","year":"2020","unstructured":"Dannen SD, Cornelison L, Durham P, Morley JE, Shahverdi K, Du J, Zhou H, Sudlow LC, Hunter D, Wood MD, et al. New in vitro highly cytotoxic platinum and palladium cyanoximates with minimal side effects in vivo. J Inorg Biochem. 2020;208:111082.","journal-title":"J Inorg Biochem"},{"issue":"51","key":"453_CR7","doi-asserted-by":"publisher","first-page":"eadc9245","DOI":"10.1126\/sciadv.adc9245","volume":"8","author":"J Liu","year":"2022","unstructured":"Liu J, Lane S, Lall R, Russo M, Farrell L, Debreli Coskun M, Curtin C, Araujo-Gutierrez R, Scherrer-Crosbie M, Trachtenberg BH, et al. Circulating hemopexin modulates anthracycline cardiac toxicity in patients and in mice. Sci Adv. 2022;8(51):eadc9245.","journal-title":"Sci Adv"},{"issue":"4","key":"453_CR8","doi-asserted-by":"publisher","first-page":"214","DOI":"10.2174\/157340311799960645","volume":"7","author":"M Volkova","year":"2011","unstructured":"Volkova M, Russell R. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev. 2011;7(4):214\u201320.","journal-title":"Curr Cardiol Rev"},{"key":"453_CR9","first-page":"13","volume":"5","author":"C Yuan","year":"2019","unstructured":"Yuan C, Parekh H, Allegra C, George TJ, Starr JS. 5-FU induced cardiotoxicity: case series and review of the literature. Cardiooncology. 2019;5:13\u201313.","journal-title":"Cardiooncology"},{"issue":"2","key":"453_CR10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.cpt.2024.04.004","volume":"3","author":"B Rachma","year":"2025","unstructured":"Rachma B, Savitri M, Sutanto H. Cardiotoxicity in platinum-based chemotherapy: Mechanisms, manifestations, and management. Cancer Pathog Ther. 2025;3(2):101\u20138.","journal-title":"Cancer Pathog Ther"},{"issue":"1\u20132","key":"453_CR11","first-page":"52","volume":"41","author":"K Weidner","year":"2018","unstructured":"Weidner K, Behnes M, Haas J, Rusnak J, Fuerner P, Kuska M, Mukherji A, Borggrefe M, Hofheinz RD, Akin I. Oxaliplatin-Induced acute ST segment elevation mimicking myocardial infarction: A case report. Oncol Res Treat. 2018;41(1\u20132):52\u20136.","journal-title":"Oncol Res Treat"},{"issue":"1","key":"453_CR12","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1080\/02841860802199816","volume":"48","author":"L Woei Chung","year":"2009","unstructured":"Woei Chung L, Liao Y-M, Hsieh C-Y, Lin C-Y. Oxaliplatin-induced long QT syndrome in a patient with appendiceal adenocarcinoma. Acta Oncol. 2009;48(1):156\u20137.","journal-title":"Acta Oncol"},{"key":"453_CR13","doi-asserted-by":"publisher","first-page":"900406","DOI":"10.3389\/fcvm.2022.900406","volume":"9","author":"X Chen","year":"2022","unstructured":"Chen X, Wang H, Zhang Z, Xu Y, An X, Ai X, Li L. Case report: Oxaliplatin-Induced Third-Degree atrioventricular block: first discovery of an important Side-Effect. Front Cardiovasc Med. 2022;9:900406.","journal-title":"Front Cardiovasc Med"},{"issue":"11","key":"453_CR14","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.ejca.2005.03.027","volume":"41","author":"M Ng","year":"2005","unstructured":"Ng M, Cunningham D, Norman AR. The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). Eur J Cancer. 2005;41(11):1542\u20136.","journal-title":"Eur J Cancer"},{"issue":"4","key":"453_CR15","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.jaccao.2020.06.012","volume":"2","author":"A Padegimas","year":"2020","unstructured":"Padegimas A, Carver JR. How to diagnose and manage patients with Fluoropyrimidine-Induced chest pain: A single center approach. JACC CardioOncol. 2020;2(4):650\u20134.","journal-title":"JACC CardioOncol"},{"issue":"6","key":"453_CR16","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S1470-2045(14)70105-6","volume":"15","author":"J Primrose","year":"2014","unstructured":"Primrose J, Falk S, Finch-Jones M, Valle J, O\u2019Reilly D, Siriwardena A, Hornbuckle J, Peterson M, Rees M, Iveson T, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the new EPOC randomised controlled trial. Lancet Oncol. 2014;15(6):601\u201311.","journal-title":"Lancet Oncol"},{"key":"453_CR17","doi-asserted-by":"publisher","first-page":"117954681986644","DOI":"10.1177\/1179546819866445","volume":"13","author":"IE Perez","year":"2019","unstructured":"Perez IE, Taveras Alam S, Hernandez GA, Sancassani R. Cancer therapy-related cardiac dysfunction: an overview for the clinician. Clin Med Insights: Cardiol. 2019;13:1179546819866445.","journal-title":"Clin Med Insights: Cardiol"},{"issue":"22","key":"453_CR18","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","volume":"131","author":"D Cardinale","year":"2015","unstructured":"Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, Civelli M, Lamantia G, Colombo N, Curigliano G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981\u20138.","journal-title":"Circulation"},{"issue":"4","key":"453_CR19","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/bjc.2013.445","volume":"109","author":"LD van Schinkel","year":"2013","unstructured":"van Schinkel LD, Willemse PM, van der Meer RW, Burggraaf J, van Elderen SG, Smit JW, de Roos A, Osanto S, Lamb HJ. Chemotherapy for testicular cancer induces acute alterations in diastolic heart function. Br J Cancer. 2013;109(4):891\u20136.","journal-title":"Br J Cancer"},{"issue":"17","key":"453_CR20","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1161\/CIR.0b013e3182a88099","volume":"128","author":"SE Lipshultz","year":"2013","unstructured":"Lipshultz SE, Adams MJ, Colan SD, Constine LS, Herman EH, Hsu DT, Hudson MM, Kremer LC, Landy DC, Miller TL, et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American heart association. Circulation. 2013;128(17):1927\u201395.","journal-title":"Circulation"},{"issue":"4","key":"453_CR21","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.yjmcc.2011.01.007","volume":"50","author":"LC Heather","year":"2011","unstructured":"Heather LC, Clarke K. Metabolism, hypoxia and the diabetic heart. J Mol Cell Cardiol. 2011;50(4):598\u2013605.","journal-title":"J Mol Cell Cardiol"},{"key":"453_CR22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3389\/fcvm.2018.00068","volume":"5","author":"QG Karwi","year":"2018","unstructured":"Karwi QG, Uddin GM, Ho KL, Lopaschuk GD. Loss of metabolic flexibility in the failing heart. Front Cardiovasc Med. 2018;5:68.","journal-title":"Front Cardiovasc Med"},{"key":"453_CR23","first-page":"e21","volume":"52","author":"C Constantinides","year":"2011","unstructured":"Constantinides C, Mean R, Janssen BJ. Effects of isoflurane anesthesia on the cardiovascular function of the C57BL\/6 mouse. ILAR journal\/National Res Council Inst Lab Anim Resour. 2011;52:e21.","journal-title":"ILAR journal\/National Res Council Inst Lab Anim Resour"},{"issue":"10","key":"453_CR24","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1161\/hc1002.105225","volume":"105","author":"M Asakawa","year":"2002","unstructured":"Asakawa M, Takano H, Nagai T, Uozumi H, Hasegawa H, Kubota N, Saito T, Masuda Y, Kadowaki T, Komuro I. Peroxisome proliferator-activated receptor \u03b3 plays a critical role in Inhibition of cardiac hypertrophy in vitro and in vivo. Circulation. 2002;105(10):1240\u20136.","journal-title":"Circulation"},{"key":"453_CR25","first-page":"385","volume":"78","author":"C Cunha DFd","year":"2002","unstructured":"Cunha DFd C, SFdCd. Reis MAd, Teixeira vdpa: heart weight and heart weight\/body weight coefficient in malnourished adults. Arquivos Brasileiros De Cardiologia. 2002;78:385\u20137.","journal-title":"Arquivos Brasileiros De Cardiologia"},{"issue":"D1","key":"453_CR26","doi-asserted-by":"publisher","first-page":"D607","DOI":"10.1093\/nar\/gky1131","volume":"47","author":"D Szklarczyk","year":"2019","unstructured":"Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607\u201313.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"453_CR27","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.cell.2018.02.014","volume":"173","author":"TMA Mohamed","year":"2018","unstructured":"Mohamed TMA, Ang YS, Radzinsky E, Zhou P, Huang Y, Elfenbein A, Foley A, Magnitsky S, Srivastava D. Regulation of cell cycle to stimulate adult cardiomyocyte proliferation and cardiac regeneration. Cell. 2018;173(1):104\u2013e116112.","journal-title":"Cell"},{"issue":"12","key":"453_CR28","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1042\/CS20211180","volume":"136","author":"D Mahiny-Shahmohammady","year":"2022","unstructured":"Mahiny-Shahmohammady D, Hauck L, Billia F. Defining the molecular underpinnings controlling cardiomyocyte proliferation. Clin Sci (Lond). 2022;136(12):911\u201334.","journal-title":"Clin Sci (Lond)"},{"issue":"1","key":"453_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27\u201330.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"453_CR30","doi-asserted-by":"publisher","first-page":"e96736","DOI":"10.1371\/journal.pone.0096736","volume":"9","author":"D Skovgaard","year":"2014","unstructured":"Skovgaard D, Hasbak P, Kjaer A. BNP predicts chemotherapy-related cardiotoxicity and death: comparison with gated equilibrium radionuclide ventriculography. PLoS ONE. 2014;9(5):e96736.","journal-title":"PLoS ONE"},{"issue":"10","key":"453_CR31","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1139\/cjpp-2019-0700","volume":"98","author":"Y Tian","year":"2020","unstructured":"Tian Y, Lv W, Lu C, Jiang Y, Yang X, Song M. Galectin-3 Inhibition attenuates doxorubicin-induced cardiac dysfunction by upregulating the expression of peroxiredoxin-4. Can J Physiol Pharmacol. 2020;98(10):700\u20137.","journal-title":"Can J Physiol Pharmacol"},{"issue":"6","key":"453_CR32","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1093\/cvr\/cvaa233","volume":"117","author":"M Vigil-Garcia","year":"2020","unstructured":"Vigil-Garcia M, Demkes CJ, Eding JEC, Versteeg D, de Ruiter H, Perini I, Kooijman L, Gladka MM, Asselbergs FW, Vink A, et al. Gene expression profiling of hypertrophic cardiomyocytes identifies new players in pathological remodelling. Cardiovascular Res. 2020;117(6):1532\u201345.","journal-title":"Cardiovascular Res"},{"issue":"1","key":"453_CR33","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1161\/CIRCRESAHA.116.308030","volume":"119","author":"SA Dick","year":"2016","unstructured":"Dick SA, Epelman S. Chronic heart failure and inflammation. Circul Res. 2016;119(1):159\u201376.","journal-title":"Circul Res"},{"issue":"7","key":"453_CR34","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/ejhf.1758","volume":"22","author":"J Tromp","year":"2020","unstructured":"Tromp J, Boerman LM, Sama IE, Maass S, Maduro JH, Hummel YM, Berger MY, de Bock GH, Gietema JA, Berendsen AJ, et al. Long-term survivors of early breast cancer treated with chemotherapy are characterized by a pro-inflammatory biomarker profile compared to matched controls. Eur J Heart Fail. 2020;22(7):1239\u201346.","journal-title":"Eur J Heart Fail"},{"issue":"15","key":"453_CR35","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1093\/cvr\/cvad140","volume":"119","author":"B Kattih","year":"2023","unstructured":"Kattih B, Boeckling F, Shumliakivska M, Tombor L, Rasper T, Schmitz K, Hoffmann J, Nicin L, Abplanalp WT, Carstens DC, et al. Single-nuclear transcriptome profiling identifies persistent fibroblast activation in hypertrophic and failing human hearts of patients with longstanding disease. Cardiovascular Res. 2023;119(15):2550\u201362.","journal-title":"Cardiovascular Res"},{"key":"453_CR36","doi-asserted-by":"publisher","unstructured":"Iso T, Kurabayashi M. Cardiac metabolism and contractile function in mice with reduced Trans-Endothelial fatty acid transport. Metabolites. 2021;11(12):889.\u00a0https:\/\/doi.org\/10.3390\/metabo11120889.","DOI":"10.3390\/metabo11120889"},{"key":"453_CR37","doi-asserted-by":"crossref","unstructured":"Goulbourne Chris N, Gin P, Tatar A, Nobumori C, Hoenger A, Jiang H, et al. The GPIHBP1\u2013LPL complex is responsible for the margination of triglyceride-rich lipoproteins in capillaries. Cell Metab. 2014;19(5):849\u201360.","DOI":"10.1016\/j.cmet.2014.01.017"},{"issue":"11","key":"453_CR38","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1210\/me.2008-0146","volume":"22","author":"BS Davies","year":"2008","unstructured":"Davies BS, Waki H, Beigneux AP, Farber E, Weinstein MM, Wilpitz DC, Tai L-J, Evans RM, Fong LG, Tontonoz P. The expression of GPIHBP1, an endothelial cell binding site for lipoprotein lipase and chylomicrons, is induced by peroxisome proliferator-activated receptor-\u03b3. Mol Endocrinol. 2008;22(11):2496\u2013504.","journal-title":"Mol Endocrinol"},{"issue":"6","key":"453_CR39","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.cmet.2012.04.006","volume":"15","author":"IJ Goldberg","year":"2012","unstructured":"Goldberg IJ, Trent CM, Schulze PC. Lipid metabolism and toxicity in the heart. Cell Metabol. 2012;15(6):805\u201312.","journal-title":"Cell Metabol"},{"issue":"3","key":"453_CR40","doi-asserted-by":"publisher","first-page":"R173","DOI":"10.1530\/JOE-17-0031","volume":"233","author":"R Rodr\u00edguez-Calvo","year":"2017","unstructured":"Rodr\u00edguez-Calvo R, Girona J, Alegret JM, Bosquet A, Ibarretxe D, Masana L. Role of the fatty acid-binding protein 4 in heart failure and cardiovascular disease. J Endocrinol. 2017;233(3):R173\u201384.","journal-title":"J Endocrinol"},{"issue":"1","key":"453_CR41","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1152\/physrev.00015.2009","volume":"90","author":"GD Lopaschuk","year":"2010","unstructured":"Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev. 2010;90(1):207\u201358.","journal-title":"Physiol Rev"},{"issue":"1","key":"453_CR42","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/BF03194597","volume":"47","author":"A Chmurzy\u0144ska","year":"2006","unstructured":"Chmurzy\u0144ska A. The multigene family of fatty acid-binding proteins (FABPs): function, structure and polymorphism. J Appl Genet. 2006;47(1):39\u201348.","journal-title":"J Appl Genet"},{"key":"453_CR43","unstructured":"Hall JE, Hall ME. Guyton and hall textbook of medical physiology e-Book. Elsevier Health Sciences; 2020."},{"issue":"6","key":"453_CR44","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1128\/MCB.01085-10","volume":"31","author":"JM Ellis","year":"2011","unstructured":"Ellis JM, Mentock SM, Depetrillo MA, Koves TR, Sen S, Watkins SM, Muoio DM, Cline GW, Taegtmeyer H, Shulman GI, et al. Mouse cardiac acyl coenzyme a synthetase 1 deficiency impairs fatty acid oxidation and induces cardiac hypertrophy. Mol Cell Biol. 2011;31(6):1252\u201362.","journal-title":"Mol Cell Biol"},{"issue":"4","key":"453_CR45","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1194\/jlr.M013292","volume":"52","author":"DL Golej","year":"2011","unstructured":"Golej DL, Askari B, Kramer F, Barnhart S, Vivekanandan-Giri A, Pennathur S, Bornfeldt KE. Long-chain acyl-CoA synthetase 4 modulates prostaglandin E\u2082 release from human arterial smooth muscle cells. J Lipid Res. 2011;52(4):782\u201393.","journal-title":"J Lipid Res"},{"issue":"5","key":"453_CR46","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s10545-010-9061-2","volume":"33","author":"SM Houten","year":"2010","unstructured":"Houten SM, Wanders RJ. A general introduction to the biochemistry of mitochondrial fatty acid \u03b2-oxidation. J Inherit Metab Dis. 2010;33(5):469\u201377.","journal-title":"J Inherit Metab Dis"},{"issue":"5\u20136","key":"453_CR47","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.mam.2004.06.004","volume":"25","author":"J-P Bonnefont","year":"2004","unstructured":"Bonnefont J-P, Djouadi F, Prip-Buus C, Gobin S, Munnich A, Bastin J. Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. Mol Aspects Med. 2004;25(5\u20136):495\u2013520.","journal-title":"Mol Aspects Med"},{"key":"453_CR48","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/srep00079","volume":"1","author":"LP Shriver","year":"2011","unstructured":"Shriver LP, Manchester M. Inhibition of fatty acid metabolism ameliorates disease activity in an animal model of multiple sclerosis. Sci Rep. 2011;1:79.","journal-title":"Sci Rep"},{"issue":"2","key":"453_CR49","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/S0021-9258(18)48391-3","volume":"267","author":"Y Uchida","year":"1992","unstructured":"Uchida Y, Izai K, Orii T, Hashimoto T. Novel fatty acid beta-oxidation enzymes in rat liver mitochondria. II. Purification and properties of enoyl-coenzyme A (CoA) hydratase\/3-hydroxyacyl-CoA dehydrogenase\/3-ketoacyl-CoA thiolase trifunctional protein. J Biol Chem. 1992;267(2):1034\u201341.","journal-title":"J Biol Chem"},{"issue":"2","key":"453_CR50","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1203\/01.PDR.0000103931.80055.06","volume":"55","author":"U Spiekerkoetter","year":"2004","unstructured":"Spiekerkoetter U, Khuchua Z, Yue Z, Bennett MJ, Strauss AW. General mitochondrial trifunctional protein (TFP) deficiency as a result of either alpha- or beta-subunit mutations exhibits similar phenotypes because mutations in either subunit alter TFP complex expression and subunit turnover. Pediatr Res. 2004;55(2):190\u20136.","journal-title":"Pediatr Res"},{"issue":"4","key":"453_CR51","doi-asserted-by":"publisher","first-page":"S884","DOI":"10.3945\/ajcn.110.001917","volume":"93","author":"PJ Fernandez-Marcos","year":"2011","unstructured":"Fernandez-Marcos PJ, Auwerx J. Regulation of PGC-1\u03b1, a nodal regulator of mitochondrial biogenesis. Am J Clin Nutr. 2011;93(4):S884\u201390.","journal-title":"Am J Clin Nutr"},{"issue":"7","key":"453_CR52","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1172\/JCI10268","volume":"106","author":"JJ Lehman","year":"2000","unstructured":"Lehman JJ, Barger PM, Kovacs A, Saffitz JE, Medeiros DM, Kelly DP. Peroxisome proliferator\u2013activated receptor \u03b3 coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Investig. 2000;106(7):847\u201356.","journal-title":"J Clin Investig"},{"issue":"7","key":"453_CR53","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1161\/CIRCRESAHA.119.315529","volume":"125","author":"X Zhu","year":"2019","unstructured":"Zhu X, Shen W, Yao K, Wang H, Liu B, Li T, Song L, Diao D, Mao G, Huang P. Fine-tuning of PGC1\u03b1 expression regulates cardiac function and longevity. Circul Res. 2019;125(7):707\u201319.","journal-title":"Circul Res"},{"issue":"16","key":"453_CR54","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1161\/01.CIR.0000034049.61181.F3","volume":"106","author":"R Liao","year":"2002","unstructured":"Liao R, Jain M, Cui L, D\u2019Agostino J, Aiello F, Luptak I, Ngoy S, Mortensen RM, Tian R. Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice. Circulation. 2002;106(16):2125\u201331.","journal-title":"Circulation"},{"issue":"12","key":"453_CR55","doi-asserted-by":"publisher","first-page":"e012673","DOI":"10.1161\/JAHA.119.012673","volume":"8","author":"DH Tran","year":"2019","unstructured":"Tran DH, Wang ZV. Glucose metabolism in cardiac hypertrophy and heart failure. J Am Heart Association. 2019;8(12):e012673.","journal-title":"J Am Heart Association"},{"issue":"4","key":"453_CR56","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/0002-9343(54)90365-4","volume":"16","author":"R Bing","year":"1954","unstructured":"Bing R, Siegel A, Ungar I, Gilbert M. Metabolism of the human heart: II. Studies on fat, ketone and amino acid metabolism. Am J Med. 1954;16(4):504\u201315.","journal-title":"Am J Med"},{"issue":"9","key":"453_CR57","doi-asserted-by":"publisher","first-page":"e0238164","DOI":"10.1371\/journal.pone.0238164","volume":"15","author":"JG Lees","year":"2020","unstructured":"Lees JG, White D, Keating BA, Barkl-Luke ME, Makker PGS, Goldstein D, Moalem-Taylor G. Oxaliplatin-induced haematological toxicity and splenomegaly in mice. PLoS ONE. 2020;15(9):e0238164.","journal-title":"PLoS ONE"},{"issue":"4","key":"453_CR58","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/mus.25966","volume":"57","author":"CE Feather","year":"2018","unstructured":"Feather CE, Lees JG, Makker PGS, Goldstein D, Kwok JB, Moalem-Taylor G, Polly P. Oxaliplatin induces muscle loss and muscle-specific molecular changes in mice. Muscle Nerve. 2018;57(4):650\u20138.","journal-title":"Muscle Nerve"},{"key":"453_CR59","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3389\/fphar.2017.00137","volume":"8","author":"JC Sorensen","year":"2017","unstructured":"Sorensen JC, Petersen AC, Timpani CA, Campelj DG, Cook J, Trewin AJ, Stojanovska V, Stewart M, Hayes A, Rybalka E. BGP-15 protects against oxaliplatin-induced skeletal myopathy and mitochondrial reactive oxygen species production in mice. Front Pharmacol. 2017;8:137.","journal-title":"Front Pharmacol"},{"issue":"11","key":"453_CR60","first-page":"1893","volume":"74","author":"JA Doust","year":"2006","unstructured":"Doust JA, Lehman R, Glasziou P. The role of BNP testing in heart failure. Am Family Phys. 2006;74(11):1893\u20138.","journal-title":"Am Family Phys"},{"issue":"2","key":"453_CR61","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ygeno.2014.12.002","volume":"105","author":"Y Liu","year":"2015","unstructured":"Liu Y, Morley M, Brandimarto J, Hannenhalli S, Hu Y, Ashley EA, Tang WH, Moravec CS, Margulies KB, Cappola TP, et al. RNA-Seq identifies novel myocardial gene expression signatures of heart failure. Genomics. 2015;105(2):83\u20139.","journal-title":"Genomics"},{"key":"453_CR62","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.gene.2019.05.003","volume":"707","author":"H Kuivaniemi","year":"2019","unstructured":"Kuivaniemi H, Tromp G. Type III collagen (COL3A1): gene and protein structure, tissue distribution, and associated diseases. Gene. 2019;707:151\u201371.","journal-title":"Gene"},{"key":"453_CR63","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/bs.pmbts.2017.02.001","volume":"147","author":"KY DeLeon-Pennell","year":"2017","unstructured":"DeLeon-Pennell KY, Meschiari CA, Jung M, Lindsey ML. Matrix metalloproteinases in myocardial infarction and heart failure. Prog Mol Biol Transl Sci. 2017;147:75\u2013100.","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"6","key":"453_CR64","doi-asserted-by":"publisher","first-page":"H1552","DOI":"10.1152\/ajpheart.00182.2019","volume":"316","author":"QAJ Hagdorn","year":"2019","unstructured":"Hagdorn QAJ, Bossers GPL, Koop AC, Piek A, Eijgenraam TR, van der Feen DE, Sillj\u00e9 HHW, de Boer RA, Berger RMF. A novel method optimizing the normalization of cardiac parameters in small animal models: the importance of dimensional indexing. Am J Physiol Heart Circ Physiol. 2019;316(6):H1552\u20137.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"7","key":"453_CR65","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.cardfail.2023.10.477","volume":"30","author":"ANR Diaz","year":"2024","unstructured":"Diaz ANR, Hurtado GP, Manzano AAA, Keyes MJ, Turissini C, Choudhary A, Curtin C, Dommaraju S, Warack S, Strom JB, et al. Sex differences in the development of Anthracycline-Associated heart failure. J Card Fail. 2024;30(7):907\u201314.","journal-title":"J Card Fail"},{"issue":"6","key":"453_CR66","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s10741-019-09820-2","volume":"24","author":"C Cadeddu Dessalvi","year":"2019","unstructured":"Cadeddu Dessalvi C, Pepe A, Penna C, Gimelli A, Madonna R, Mele D, Monte I, Novo G, Nugara C, Zito C, et al. Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens. Heart Fail Rev. 2019;24(6):915\u201325.","journal-title":"Heart Fail Rev"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-026-00453-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-026-00453-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-026-00453-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T16:03:06Z","timestamp":1774022586000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40959-026-00453-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["453"],"URL":"https:\/\/doi.org\/10.1186\/s40959-026-00453-7","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M. B. is the founder and owner of the company HSpeQ LLC and a consultant for Daxor Inc and Sarya LLC. The other authors declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}